A Study to Assess Pharmacokinetic, Pharmacodynamic, Safety and Tolerability of ASKP1240 in de Novo Kidney Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

November 17, 2010

Primary Completion Date

January 23, 2012

Study Completion Date

January 23, 2012

Conditions
Kidney Transplantation
Interventions
DRUG

bleselumab

Intravenous (IV) infusion

DRUG

Placebo

Intravenous (IV) infusion

Trial Locations (21)

17104

Central Pennsylvania Transplant Associates, Harrisburg

27599

University of North Carolina at Chapel Hill, Chapel Hill

27710

Duke University Medical Center, Durham

30322

Emory University, Atlanta

38104

Methodist University Hospital, Memphis

45219

Christ Hospital, Cincinnati

University of Cincinnati - University Internal Medicine Associates, Cincinnati

48109

University of Michigan, Ann Arbor

53705

University of Wisconsin, Madison

60153

Loyola University Medical Center, Maywood

60612

University of Illinois Medical Center, Chicago

75246

Baylor University Medical Center, Dallas

77030

The Methodist Hospital, Houston

80045

University of Colorado Denver, Aurora

84132

University of Utah Hospital, Salt Lake City

92123

California Institute of Renal Research, San Diego

94115

California Pacific Medical Center, San Francisco

94143

UCSF Medical Center, San Francisco

94304

Stanford University Medical Center, Palo Alto

02215

Beth Israel Deaconess Medical Center, The Transplant Institute, Boston

07039

St. Barnabas Medical Center, Livingston

Sponsors
All Listed Sponsors
collaborator

Kyowa Kirin Co., Ltd.

INDUSTRY

lead

Astellas Pharma Inc

INDUSTRY